Hybrid Radionuclide Therapy Intensifies Treatment of NET Liver Metastases while Maintaining Whole-Bo
November 12, 2026
November 12, 2026
RESTON, Virginia, Nov. 12 [Category: Medical] -- The Society of Nuclear Medicine and Molecular Imaging posted the following news release:
* * *
Hybrid Radionuclide Therapy Intensifies Treatment of NET Liver Metastases while Maintaining Whole-Bo
*
Reston, VA (November 12, 2026)--Combining intraarterial and intravenous administration of peptide receptor radionuclide therapy (PRRT) can selectively intensify treatment for liver-dominant metastatic . . .
* * *
Hybrid Radionuclide Therapy Intensifies Treatment of NET Liver Metastases while Maintaining Whole-Bo
*
Reston, VA (November 12, 2026)--Combining intraarterial and intravenous administration of peptide receptor radionuclide therapy (PRRT) can selectively intensify treatment for liver-dominant metastatic . . .